Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Long-term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoiesis Stimulating Agent Treatment

NCT02779764 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02779764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02779764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Long-term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoiesis Stimulating Agent Treatment
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
May 16, 2016
Completion date
November 28, 2017
Enrollment
164 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

hemodialysis patients with renal anemia